&nbsp;

Dec 2024

Drug

temsirolimus

Other Name(s): Torisel ®

Quick Link(s):

Jun 2024

Regimen

TEMS

Cancer Type:

Genitourinary,

Renal cell / Kidney

Intent: Palliative

Funding:

New Drug Funding Program

Temsirolimus - Metastatic Renal Cell Carcinoma

Drugs Used:

temsirolimus

Quick Link(s):

Regimen Monograph

Jun 2024

Regimen

TRAS

Cancer Type:

Breast

Intent: Palliative

Funding:

New Drug Funding Program

Trastuzumab (Biosimilar) in combination with Chemotherapy - Metastatic Breast Cancer

New Drug Funding Program

Trastuzumab (Biosimilar) - Second Line - Metastatic Breast Cancer

Drugs Used:

trastuzumab

Quick Link(s):

Regimen Monograph

May 2024

Regimen

TMZL

Cancer Type:

Gastrointestinal,

Neuroendocrine (GI),

Lung,

Neuroendocrine (Lung)

Intent: Palliative

Funding:

ODB - General Benefit

temozolomide

Drugs Used:

temozolomide

Quick Link(s):

Regimen Monograph

Jun 2024

Drug

trifluridine / tipiracil

Other Name(s): Lonsurf®

Quick Link(s):

Nov 2024

Regimen

TRAS

Cancer Type:

Gynecologic,

Endometrial

Intent: Palliative, Curative

Funding:

New Drug Funding Program

Trastuzumab (Biosimilar) - Advanced or Recurrent Endometrial Cancer

Drugs Used:

trastuzumab

Quick Link(s):

Regimen Monograph

Oct 2024

Guidelines and Advice

Hereditary Cancer Testing Eligibility Criteria: Version 3.1

Status: Current
Version: 3.1

Oct 2024

Regimen

TRIFTIPI+BEVA

Cancer Type:

Gastrointestinal,

Colorectal,

Small bowel and appendix

Intent: Palliative

Funding:

Exceptional Access Program

trifluridine / tipiracil - In combination with bevacizumab for treatment of metastatic colorectal cancer, according to clinical criteria

New Drug Funding Program

Bevacizumab (Biosimilar) - In Combination with Trifluridine and Tipiracil for Previously Treated Metastatic Colorectal Cancer

trifluridine / tipiracil,

Drugs Used:

bevacizumab

Quick Link(s):

Regimen Monograph

Nov 2024

Drug

tremelimumab

Other Name(s): Imjudo®

Quick Link(s):

Apr 2024

Regimen

TISL(MNT)

Cancer Type:

Head and Neck,

Nasopharynx

Intent: Palliative

Drugs Used:

tislelizumab (Unfunded)

Quick Link(s):

Regimen Monograph

Apr 2024

Regimen

HYPERCVAD+CALA

Cancer Type:

Hematologic,

Leukemia - Acute Lymphoblastic (ALL)

Intent: Curative

Funding:

ODB - General Benefit

dexamethasone

New Drug Funding Program

Calaspargase Pegol (Outpatient) - Newly Diagnosed Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed_Biphenotypic Leukemia

Drugs Used: